Patents Assigned to MANKIND PHARMA LTD
  • Fixed dose pharmaceutical composition of valsartan and sacubitril
    Patent number: 11819577
    Abstract: This present invention relates to pharmaceutical composition comprising fixed dose combination of valsartan or pharmaceutically acceptable salts thereof and sacubitril or pharmaceutically acceptable salts thereof. Further this invention also relates to process for the preparation of said composition and use of the said composition in treatment of certain diseases.
    Type: Grant
    Filed: June 7, 2022
    Date of Patent: November 21, 2023
    Assignee: Mankind Pharma Ltd.
    Inventors: Bharat Sharma, K. S. Hareen, P. V. S Narasimham, Anil Kumar
  • Stable pharmaceutical composition of vasopressin
    Patent number: 11707502
    Abstract: The present invention relates to a stable pharmaceutical composition comprising vasopressin or pharmaceutically acceptable salts thereof. The present invention further provides a method of increasing blood pressure in adults with vasodilatory shock by administering said pharmaceutical composition of vasopressin or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: March 29, 2022
    Date of Patent: July 25, 2023
    Assignee: Mankind Pharma Ltd.
    Inventors: Saurabh Kumar, Ankush Gupta, Hanumant Gambhire, Raghuveera H. G, P. V. S Narasimham, Anil Kumar
  • NOVEL APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS
    Publication number: 20220332700
    Abstract: The present invention relates to inhibitors of apoptosis signal-regulating kinase 1 (“ASK1”), a process for synthesis of the compounds of the present invention, composition comprising the compounds and use of the compounds for inhibition of ASK1.
    Type: Application
    Filed: June 24, 2020
    Publication date: October 20, 2022
    Applicant: MANKIND PHARMA LTD
    Inventors: Santosh Kumar RAI, Rakesh Iswar PATIL, Somnath Singha ROY, Kalicharan SHARMA, Rahul DWIVEDI, Srinivasa Reddy BAPURAM, Anil KUMAR
  • NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1
    Publication number: 20220235046
    Abstract: An object of the invention is to provide compounds as selective JAK1 inhibitor, a process for preparation of the inhibitors, a composition containing the compounds and utility of the compounds.
    Type: Application
    Filed: May 26, 2020
    Publication date: July 28, 2022
    Applicant: MANKIND PHARMA LTD.
    Inventors: Santosh Kumar RAI, Mahadev BANDGAR, Sazid ALI, Himanshu RAI, Amol Pandurang GUNJAL, Rakesh Iswar PATIL, Srinivasa Reddy BAPURAM, Anil KUMAR
  • Fixed dose pharmaceutical composition of valsartan and sacubitril
    Patent number: 11382866
    Abstract: This present invention relates to pharmaceutical composition comprising fixed dose combination of valsartan or pharmaceutically acceptable salts thereof and sacubitril or pharmaceutically acceptable salts thereof. Further this invention also relates to process for the preparation of said composition and use of the said composition in treatment of certain diseases.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: July 12, 2022
    Assignee: Mankind Pharma Ltd.
    Inventors: Bharat Sharma, K. S. Hareen, P. V. S Narasimham, Anil Kumar
  • Stable pharmaceutical composition of vasopressin
    Patent number: 11318183
    Abstract: The present invention relates to a stable pharmaceutical composition comprising vasopressin or pharmaceutically acceptable salts thereof. The present invention further provides a method of increasing blood pressure in adults with vasodilatory shock by administering said pharmaceutical composition of vasopressin or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: May 3, 2022
    Assignee: Mankind Pharma Ltd.
    Inventors: Saurabh Kumar, Ankush Gupta, Hanumant Gambhire, Raghuveera H. G, P. V. S Narasimham, Anil Kumar
  • Process for the preparation of lifitegrast
    Patent number: 11246862
    Abstract: The present invention relates to a novel process for the preparation of lifitegrast of Formula I. The present invention further provides a novel process for the purification of lifitegrast of Formula I.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: February 15, 2022
    Assignee: MANKIND PHARMA LTD.
    Inventors: Jigar Tarun Kumar Bhavsar, Rakesh Tiwari, Bhuwan Bhashkar, Anil Kumar
  • GPR119 agonist compounds
    Patent number: 10954229
    Abstract: The present invention relates to novel compounds of formula (I), process for preparation of the same and composition comprising these compounds.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: March 23, 2021
    Assignee: MANKIND PHARMA LTD.
    Inventors: Rakesh Ishwar Patil, Jeevan Verma, Puneet Kumar, Amol Pandurang Gunjal, Himanshu Rai, Santosh Kumar Rai, Anil Kumar
  • Compounds as GPR119 agonists
    Patent number: 10919915
    Abstract: The present invention relates to novel compounds of formula (I) as GPR119 agonist, composition compositions containing such compounds and method of preparation thereof.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: February 16, 2021
    Assignee: MANKIND PHARMA LTD.
    Inventors: Rakesh Ishwar Patil, Jeevan Verma, Dharmesh Shah, Sazid Ali, Srinivasa Reddy Bapuram, Santosh Kumar Rai, Anil Kumar
  • GPR119 agonist compounds
    Patent number: 10752622
    Abstract: The present invention relates to novel compounds of formula (I), process for preparation of the same and composition comprising these compounds.
    Type: Grant
    Filed: December 24, 2018
    Date of Patent: August 25, 2020
    Assignee: MANKIND PHARMA LTD.
    Inventors: Rakesh Ishwar Patil, Jeevan Verma, Puneet Kumar, Amol Pandurang Gunjal, Himanshu Rai, Santosh Kumar Rai, Anil Kumar
  • Compounds as GPR119 agonists
    Patent number: 10526345
    Abstract: The present invention relates to novel compounds of formula (I) as GPR119 agonist, composition compositions containing such compounds and method of preparation thereof.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: January 7, 2020
    Assignee: MANKIND PHARMA LTD.
    Inventors: Rakesh Ishwar Patil, Jeevan Verma, Dharmesh Shah, Sazid Ali, Srinivasa Reddy Bapuram, Santosh Kumar Rai, Anil Kumar
  • Process for the preparation of considerably pure Silodosin
    Patent number: 10377710
    Abstract: The present invention relates to a novel, improved, commercially viable and industrially advantageous process for the preparation of Silodosin of Formula (I), its pharmaceutically acceptable salts or solvates thereof. The invention relates to the preparation of considerably pure Silodosin with high yield.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: August 13, 2019
    Assignee: MANKIND PHARMA LTD.
    Inventors: Kuldeep Singh Gangwar, Anil Kumar, Bhuwan Bhashkar
  • Intermediates, their process and use in preparation of selective ?1-adrenoceptor antagonists, Silodosin
    Patent number: 10239833
    Abstract: The present invention provides novel process for the preparation of the ?1-adrenoceptor antagonists, Silodosin and its pharmaceutically acceptable salts indoline compounds, utilizing derivatives of Formula 1 and salts thereof.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: March 26, 2019
    Assignee: MANKIND PHARMA LTD.
    Inventors: Gurpreet Singh, Kuldeep Singh Gangwar, Bhuwan Bhashkar, Anil Kumar
  • GPR119 agonist compounds
    Patent number: 10208030
    Abstract: The present invention relates to novel compounds of formula (I), process for preparation of the same and composition comprising these compounds.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: February 19, 2019
    Assignee: Mankind Pharma Ltd.
    Inventors: Rakesh Ishwar Patil, Jeevan Verma, Puneet Kumar, Amol Pandurang Gunjal, Himanshu Rai, Santosh Kumar Rai, Anil Kumar
  • Fluoroquinolone carboxylic acid compounds and use thereof for the preparation of besifloxacin hydrochloride
    Patent number: 10167271
    Abstract: The present invention relates to novel fluoroquinolone carboxylic acid compounds and derivatives of Formula-I, and their salts wherein, R represents H or halogen. The present invention also relates to the use of novel fluoroquinolone carboxylic acid compounds and derivatives of Formula-I for preparation of Besifloxacin hydrochloride.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: January 1, 2019
    Assignee: MANKIND PHARMA LTD
    Inventors: Jigar Bhavsar, Bhuwan Bhashkar, Anil Kumar